Comparative Immunomodulatory Activity of Nigella sativa L. Preparations on Proinflammatory Mediators: A Focus on Asthma by Koshak, AE et al.
fphar-09-01075 October 1, 2018 Time: 16:28 # 1
ORIGINAL RESEARCH




University of Graz, Austria
Reviewed by:
Anastasia Karioti,
Aristotle University of Thessaloniki,
Greece
Roser Vila,





This article was submitted to
Ethnopharmacology,
a section of the journal
Frontiers in Pharmacology
Received: 10 January 2018
Accepted: 05 September 2018
Published: 02 October 2018
Citation:
Koshak AE, Yousif NM, Fiebich BL,
Koshak EA and Heinrich M (2018)
Comparative Immunomodulatory
Activity of Nigella sativa L.
Preparations on Proinflammatory




Activity of Nigella sativa L.
Preparations on Proinflammatory
Mediators: A Focus on Asthma
Abdulrahman E. Koshak1,2, Nizar M. Yousif3, Bernd L. Fiebich4, Emad A. Koshak5 and
Michael Heinrich2*
1 Department of Natural Products and Alternative Medicine, Faculty of Pharmacy, King Abdulaziz University, Jeddah,
Saudi Arabia, 2 Research Group Pharmacognosy and Phytotherapy, UCL School of Pharmacy, London, United Kingdom,
3 Faculty of Biology, University of Freiburg, Freiburg, Germany, 4 VivaCell Biotechnology, Denzlingen, Germany, 5 Allergy
and Clinical Immunology Division, Department of Internal Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah,
Saudi Arabia
Introduction: A range of traditional and commercial preparations of NS is frequently
used in the treatment of several inflammatory diseases. Often, these preparations have
poor preclinical characterization that may lead to variable pharmacological effects.
Objective: To assess the in vitro effects of different chemically defined preparations of
NS on some asthma-related mediators of inflammation.
Methods: Different NS preparations were obtained by either seed extraction with a
spectrum of solvents ranging from lipophilic to hydrophilic, or commercial products were
collected. The TQ concentration of NS was analyzed by HPLC. Immunomodulatory
activity was assessed by the release of mediators (IL-2, IL-6, PGE2) in primary human
T-lymphocytes, monocytes, and A549 human lung epithelial cells.
Results: Ten distinct NS preparations showed variability in TQ concentration, being
highest in the oily preparations extract-7 (2.4% w/w), followed by extract-10 (0.7%w/w).
Similarly, the release of mediators was varied, being greatest in extract-7 and 10 via
significantly (<0.05) suppressing IL-2, IL-6, and PGE2 in T-lymphocytes as well as IL-6
and PGE2 in monocytes. Also, PGE2 release in A549 cells was significantly enhanced
by both extracts.
Conclusion: The TQ concentration and in vitro activity were variable among the
different NS preparations. TQ-rich oily NS preparations produced potent favorable
immunomodulation in asthma inflammation and can be used in future studies.
Keywords: NS, black Seed, anti-inflammatory, immunomodulatory, cytokines, in vitro
Abbreviations: DMSO, dimethyl sulfoxide; DPBS, Dulbecco‘s phosphate buffered saline; HPLC, high-performance-liquid
chromatography; IL, interleukin; LPS, lipopolysaccharides; NS, Nigella sativa L.; PGE2, prostaglandin E2; SEB, Staphylococcal
enterotoxin B; TQ, thymoquinone.
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INTRODUCTION
The seeds of the plant NS family Ranunculaceae are commonly
used as a spice known as black cumin. It has traditional medical
applications and is considered to be a characteristic herbal
medicine for diverse diseases in Unani, Indian, Arabic, and
Prophetic traditional medical traditions (Ahmad et al., 2013).
Avicenna reported its benefit for shortness of breath and for
stopping phlegm (Avicenna, 1593). Dioscorides reported its
medical use for cleaning rough skin and psoriasis (Osbaldeston,
2000). Hippocrates used it for treating hepatic and digestive
conditions (Salama, 2010). Imam Ibn Qayyim Al-Jawziyya
(1292–1350 AD), the author of the Prophetic Medicine, reported
that NS alleviate gasping and hard breathing (Abdullah,
2003). In Arabia, NS is a traditional remedy for asthma,
cough, stomach ache, abdominal pain, colic, general fatigue,
rheumatism, and skin diseases (Lebling and Pepperdine,
2006).
NS seeds contain fixed oil (24.76 to 40.35%), volatile
oil (0.5 to 1.6%), quinones, alkaloids, saponins, and other
compounds in trace amounts (Liu et al., 2011; Botnick et al.,
2012; Ahmad et al., 2013). The compounds responsible for
NS’s activities are still not well-established. It is likely that
several compounds are responsible or co-responsible for NS
activity and that one must consider a specific extract as the
active ingredient rather than a single compound. TQ is the
main component of NS’s volatile oil and based on several
studies it is considered to be a key active ingredient (Ahmad
et al., 2013). Other compounds such as dithymoquinone,
thymohydroquinone, thymol, carvacrol, and α-hederin were
also reported to produce relevant pharmacological effects in
preclinical models (Marsik et al., 2005; Landa et al., 2009b;
Fallahi et al., 2016). As obvious with other herbal medicines,
the extraction method influences the chemical composition and,
consequently, the pharmacological activity of a specific NS
preparation.
The anti-inflammatory/immunomodulatory activity of NS
was recently reviewed in asthma. NS extracts and/or its
active constituents (including TQ, nigellone, and alpha-hederin)
showed anti-histaminic, anti-eosinophilic, anti-leukotrienes,
anti-immunoglobulin and reduced proinflammatory cytokines
(interleukins-2, 4, 5, 6, 12, and 13) in in vitro/in vivo models
(Koshak et al., 2017a).
Asthma is a common respiratory disease affecting about
334 million people worldwide and has become a global health
priority (Global Asthma Network, 2014). It is a chronic airway
inflammatory disease recognized by a history of respiratory
symptoms such as wheezing, shortness of breath, chest
tightness, and cough accompanied by lung hyper-responsiveness
and inflammation (Global Initiative for Asthma, 2017). The
pathology of asthma is initiated by multiple interactions
between inflammatory cells and mediators. The most important
cells involved in asthma-related inflammation are mast cells,
eosinophils, T lymphocytes, neutrophils, and epithelial cells
(Koda-Kimble, 2009). Typically in asthma, cytokines released
by Type 2 T helper (Th2) cells including interleukin-4 (IL-4),
interleukin-5 (IL-5), and interleukin-13 (IL-13) as well as
cytokines released by Type 1 T helper (Th1) cells such as
interferon-gamma are considered to be the main cytokines
triggered in asthma (Ngoc et al., 2005).
Nevertheless, other proinflammatory mediators are also
involved in asthma-related inflammation. For instance,
interleukin-2 (IL-2) was found to be increased in the broncho-
alveolar lavage fluid (BALF) of patients with asthma (Virchow
et al., 1996). IL-2 may increase the production of IL-5 and
attract eosinophils (van Haelst Pisani et al., 1991; Kuraoka et al.,
2004; Davoine and Lacy, 2014). Moreover, patients treated with
inhaled IL-2 had asthma-like signs and symptoms (Loppow
et al., 2007). Interleukin-6 (IL-6) is a major pro-inflammatory
mediator and a relevant target for several diseases (Hirano,
1998). IL-6 expression was increased in bronchial epithelial
cells of patients with asthma (Mattoli et al., 1992). In patients
with asthma, IL-6 was found at a high level in serum as well
as in BALF (Yokoyama et al., 1995; Tillie-Leblond et al., 1999).
IL-6 was elevated in stimulated sputum of allergic asthma
patients (Neveu et al., 2010). Elevated serum levels of IL-6
were found in 54% of 170 adult asthmatics (Ilmarinen et al.,
2016).
Additionally, prostaglandin E2 (PGE2) is commonly assumed
to be a proinflammatory mediator in several diseases (Sastre
and Del Pozo, 2012). PGE2 was shown to induce Th2 cell
development, Th2 cytokines secretion, and production of
immunoglobulin E (Kaur et al., 1999). However, in respiratory
diseases, PGE2 is important because of the multiplicity of its
effects on immune response. PGE2 exerts a beneficial role in
asthma via protection from lung smooth muscle proliferation
and some anti-inflammatory effects (Sastre and Del Pozo,
2012). PGE2 may reduce mast cells activity and relax smooth
muscle (Torres et al., 2015). In a clinical trial, PGE2 showed
bronchodilatory effects via inhibition of inflammatory mediators
(Chung, 2005).
The aim of this project was to compare the pharmacological
activity of different NS preparations with a defined amount of TQ.
This study investigated the activity of distinct NS preparations on
asthma-related targets such as the release of IL-2, IL-6, and PGE2
from peripheral mononuclear human blood cells and a human
epithelial cell line (A549) to provide the basis of a clinical study
(Koshak et al., 2017b).
MATERIALS AND METHODS
Initial Preparation of Nigella sativa
Samples
Two main types of NS preparations were obtained. First, a series
of laboratory prepared extracts from crude NS seeds (Bafart
Company – Jeddah, Saudi Arabia). Second, commercial NS oil
products. Whole NS seeds (10 g) were crushed and used for
preparing each of six different NS preparations (Extracts 1–6,
Table 1). One hundred milliliter of combined extraction solvent
with different ratios (ethanol:water) were used to produce the
extracts 1–5 by means of maceration over 72 h and extract
6 by means of decoction as following; extract no.1 (100:0),
2 (80:20), 3 (60:40), 4 (30:70), 5 (0:100), 6 (0:100 boiled for
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Type of extract Thymoquinone
concentration (w/w) %
Extract 1 100% Ethanol 0.4%
Extract 2 80% Ethanol: 20% Water 0.01%
Extract 3 60% Ethanol: 40% Water 0.04%
Extract 4 30% Ethanol: 70% Water 0.005%
Extract 5 100% Water <0.005%
Extract 6 100% Boiled water (30 min boiling) Not detected
Extract 7 Super critical fluid (SCF) extract (Sami
Labs Ltd., India)
2.4%
Extract 8 Cold pressed NS oil capsules (The
Blessed Seeds, United Kingdom)
0.6%
Extract 9 Cold pressed NS oil capsules (Sanct
Bernhard, Germany)
0.2%
Extract 10 Cold pressed NS oil capsules
(Marnys S.A., Spain) (A licensed
herbal product in Saudi Arabia)
0.7%
Extracts 1 to 6 are laboratory prepared. Extracts 7–10 are ready-made commercial
products.
30 min). After filtration, the ethanol was evaporated using a rota
evaporator until constant volume, and then the remaining water
was removed by freeze-drying. Single extraction was carried out
for Extracts 1–6 and the extraction yields were as follows; extract
no.1 (32%), 2 (12%), 3 (10%), 4 (12%), 5 (9%), 6 (15%). On
the other hand, commercial ready-made NS oil products were
obtained from different producers (extracts 7–10) as mentioned
in Table 1. Then, all NS preparations were processed according
to the analysis step (2.2).
Analysis of Thymoquinone Concentration
Among Nigella sativa Samples
The HPLC method for the analysis of TQ was developed
using the approach of (Hadad et al., 2012). The analysis was
performed using a WATERS 2695 HPLC instrument attached
to Waters 996 Photodiode Array Detector. (HPLC-PDA). The
used HPLC column was phenomenex R© P/NO 00F-4252-E0, Desc
Luna 5u C18(2) 100 Å, size 150 × 4.6 mm 5 µ, S/NO 312985-
48.
All NS preparations were dissolved in 1 ml methanol in
1.5 ml Eppendorf tubes separately, vortexed for 10 s, and
centrifuged for 2 min at 10,000 rpm to separate any remaining
solid material. Afterwards, the supernatant was transferred to an
HPLC amber vial via 0.45 mm filter for analysis with HPLC.
Twenty microliter of each NS preparation were injected using
linear gradient methanol–water (20–80 v/v, initial concentration)
mobile phase over 10 min at gradient rate of 10%/min (80–
20 v/v, final concentration) and with 12 min running time
at 1.5 ml/min flow rate. TQ peak were detected in 10.3 min
(retention time) at wavelength 254 nm. All samples were
submitted in triplet and the average reading results were used.
Then, TQ concentrations were determined in the samples using
a calibration curve drawn from a series of known standard TQ
concentrations.
Thymoquinone (purity > 98%) by Cayman Chemicals was
used to prepare a range of serial dilutions of TQ for the calibration
curve. The peak area of each standard TQ concentration (0.005,
0.05, 0.1, 0.2, 0.4, 0.6 mg/ml) detected at wavelength 254 nm
was utilized to draw the calibration curve in Microsoft Excel.
Then, the peak area of each NS preparation (in final prepared
concentrations; extract 1 = 84, extract 2 = 36, extract 3 = 80,
extract 4 = 109, extract 5 = 138, extract 6 = 125, extract 7 = 27,
extract 8 = 64, extract 9 = 110, extract 10 = 65 mg/ml) were
employed in the calibration curve, and the TQ concentrations
were determined accordingly.
Preparation of Nigella sativa Samples for
the in vitro Analysis
Twenty milligram of each NS preparation was dissolved in 1ml
dimethyl sulfoxide (DMSO, Merck Millipore) solvent inside a
1.5-ml Eppendorf tube using a rotamixer for 10 s. This was
followed by centrifugation for 5 min at 1300 rpm for separation of
insoluble substances. Then, the clear supernatant was re-diluted
in DMSO to produce a final concentration of 10 or 100 µg/ml.
Also, the standard TQ (Sigma) was prepared by using DMSO
solvent to produce concentrations of 0.1, 1, 5, and 10 µM as
required.
Isolation of Human Peripheral
Monocytes and T-Lymphocyte Cells for
in vitro Analysis
Human blood from three different volunteer healthy donors,
at the University Medical Centre Freiburg, was obtained in
450 ml buffy coats. The isolation of human monocytes and
T-lymphocyte cells was carried out according to a standardized
protocol (Noble and Cutts, 1968; English and Andersen, 1974).
In six CELLSTAR R© (VWR) 50 ml centrifuge tubes, 25 ml of
Lymphocyte Separation Medium (LSM 1077, PAA Laboratories
GmbH) were added to each tube. Then, 20 ml of human
blood were carefully added into each tube. These tubes were
applied to centrifugation with Thermo ScientificTM MegafugeTM
at 1800 rpm and acceleration 1 for 1 h at room temperature.
After centrifugation, the phase containing mononuclear cells
was transferred to 50 ml CELLSTAR R© tube prefilled with a
10 ml of Dulbecco’s phosphate buffered saline (DPBS, GIBCO R©,
Life Technologies) solution for washing. This was completed
to 50 ml with the addition of more DPBS solution. Then,
centrifugation for 10 min at 1600 rpm, normal acceleration
and room temperature were performed. The supernatant was
discarded, and DPBS was added on top of the buffy coat layer
to fill it up to 50 ml. Afterwards, centrifugation at 1200 rpm
for 10 min; the supernatant discarded, and 20 ml of DPBS
was added with proper mixing. Additional DPBS was added to
fill the tube up to 50 ml. The last step was repeated, and the
supernatant was discarded, and the mononuclear cells remained
in the pellet. Finally, the cells were re-suspended in 50 ml
RPMI-1640 (Roswell Park Memorial Institute medium 1640, GE
Healthcare) fortified with 10% human serum (PAA Coelbe). Cells
were then seeded in the appropriate culture plates. An additional
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washing step after 1 h removed the T cells and enriches the
monocytes.
Monocytes and T-Lymphocyte Cells
Stimulation
Twenty-four-well cell culture plate was seeded with
5 × 105 cells/well resuspended in 1 ml culture medium
(RPMI 1640 + 10% human serum) and incubated at 37◦C for
1 h. Then the medium was changed, and the cells were further
incubated for another 1 h at 37◦C. Next, the NS preparations
(10 and 100 µg/ml) and standard TQ (10 µM) were added to
the respective wells. Generally, in each plate, two wells without
extracts served as positive (cells + stimulant + DMSO) and
negative (cells + DMSO) controls. After 30 min of incubation
with the extracts, monocytes were stimulated with 10 ng/ml of
LPS (from Salmonella enterica serotype typhimurium, Sigma-
Aldrich) and T-lymphocytes were stimulated with 100 ng/ml
staphylococcal enterotoxin B (SEB, Sigma-Aldrich). Cells were
then incubated for 24 h in 5% CO2 at 37◦C.
Human Lung Epithelial Cells (A549)
Stimulation
A549 cells (Sigma-Aldrich) were seeded (5× 105 cells/well) in 24-
well plates and treated with 50 µl/well of each NS preparation (in
concentrations of 10 and 100 µg/ml) and standard TQ (10 µM).
In each plate, two wells without extracts served as a positive
(cells + stimulant + DMSO) and negative (cells + DMSO)
controls. After 30 min of incubation, 20 µl of the stimulant IL-1β
(10 U/ml) (Roche Life Science) was added to all wells containing
extracts and the positive control. All plates were further incubated
for 24 h in 5% CO2 at 37◦C before the supernatant was harvested
for measurements.
Enzyme-Linked Immunosorbent Assay
for Interleukin-6, Interleukin-2, and
Prostaglandin E2 Determination
After the end of the incubation period, supernatants were
collected and centrifuged at 1000 g for 5 min at 4◦C.
PGE2 production were assessed in the supernatants with
a commercially available enzyme immunoassay (EIA) kits
(Biotrend, Cologne, Germany or Cayman Chemicals, Ann Arbor,
Michigan, United States, respectively, and the cytokines IL-6, IL-2
by enzyme-linked immunosorbent assay (ELISA) kits according
to the manufacturer’s instructions (Human IL-6 ELISA ready-
SET-GO kit by eBioscience; Human IL-2 ELISA kit by R&D
Systems). All experiments were replicated at least three times with
different preparations of cells from different blood donors or cell
line.
Statistical Analysis
The results were statistically analyzed using one-way ANOVA
with post hoc Dunnett’s test to investigate significant effects
of each NS preparation against the control group. For
each experiment, P value < 0.05 was considered statistically
significant.
Consent Procedure for Human Blood
Samples
Buffy coats from healthy blood donors were obtained from
the Institute of Cell and Gene therapy, University Hospital
of Freiburg under approval from the local ethical committee
(University of Freiburg).
RESULTS
Nigella sativa Preparations and Their
Thymoquinone Content
Ten different NS preparations, which varied in their TQ
concentrations, were used in this study to compare their
anti-inflammatory effects in primary human monocytes and
T-lymphocytes as well as in lung epithelial cells (A549) (Table 1).
The levels of TQ in the NS preparations can be attributed to
the extraction and preparation methods as well as the origins of
the NS seeds. Among the commercial NS preparations (Extracts 7
to 10), extract 7 had the highest concentration of TQ, followed by
extract 10. Among the laboratory prepared extracts (Extracts 1 to
6), extract 1 showed the highest level of TQ due to the solubility
characteristics of TQ, which is highly soluble in organic solvents
(Table 1).
Effect of Nigella sativa Preparations on
Inflammatory Mediators of Human
T-Lymphocytes
The effect of NS preparations on the release of the inflammatory
mediators IL-2, IL-6, and PGE2 was investigated in SEB-induced
human T-lymphocytes. All NS preparations suppressed SEB-
induced IL-2 release from T-lymphocytes, which was significant
(by more than 50%) with extracts 1, 2, 3, 5, 7, 8, and 10. TQ
potently prevented SEB-induced IL-2 release with the dose of
10 µM (Figure 1). The ethanolic and oily extracts 1, 7, and
10 significantly reduced (by more than 50%) SEB-induced IL-6
release from T-lymphocyte cells (Figure 2). Conversely, SEB-
induced IL-6 release from T-lymphocytes was further increased
with water or mixed (water/ethanol) extracts 3, 4, 5, and 6.
TQ potently prevented SEB-induced IL-2 release in the doses
of 1 and 10 µM (Figure 2). SEB-induced PGE2 release from
T-lymphocytes was significantly inhibited (by more than 50%)
with the oily extracts 7 and 10 (Figure 3). Conversely, there
was a significant enhancement of PGE2 release (by more than
150%) with the mixed (water/ethanol) extracts, and particularly
with pure water extracts (by up to 10 times). TQ potently
prevented SEB-induced PGE2 release in the doses of 1 and 10 µM
(Figure 3).
Effect of Nigella sativa Preparations on
Inflammatory Mediators in Human
Monocytes
The effects of NS preparations on the release of inflammatory
mediators IL-6 and PGE2 was investigated in LPS-induced
monocytes. A suppression of LPS-induced IL-6 release in human
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FIGURE 1 | Effects of NS preparations on interleukin-2 production by SEB-induced T-lymphocyte cells (n = 3). Significant effects are indicated by an asterisk
(∗∗∗P < 0.001).
FIGURE 2 | Effects of NS preparations on interleukin-6 production by SEB-induced T-lymphocyte cells (n = 3). Significant effects are indicated by asterisks
(∗P < 0.05, ∗∗∗P < 0.001).
monocytes was observed with most extracts, and a significant
inhibition occurred (by more than 50%) with the ethanolic and
oily extracts 1, 7, 8, and 10 (Figure 4). Additionally, LPS-induced
PGE2 release was significantly suppressed in monocytes (by
more than 50%) with the ethanolic and oily extracts 1, 7, 8,
and 10 (Figure 5). TQ potently prevented LPS-induced IL-6
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FIGURE 3 | Effects of NS preparations on prostaglandin E2 production by SEB-induced T-lymphocyte cells (n = 3). Significant effects are indicated by asterisks
(∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001).
and PGE2 release in the doses of 10 µM (Figures 4, 5 right
columns).
Effect of Nigella sativa Preparations on
Inflammatory Mediators of A549 Human
Lung Epithelial Cells
We did not observe significant inhibition of IL-1β-induced IL-6
release by any one of the NS preparations and TQ in A549 lung
epithelial cells (Figure 6). However, extracts 6 and 7 showed a
slight tendency to inhibit IL-6 release in IL-1β-induced A549 lung
epithelial cells. Conversely, the release of IL-1β-induced PGE2
was markedly (by more than 150%) increased with extracts 1, 2,
6, 7, 8, and 10. More interestingly, the release of IL-1β-induced
PGE2 with TQ was over the detection limit (Figure 7).
Summary of the Effects of Nigella sativa
Preparations on the Release of
Inflammatory Mediators in Pre-clinical
in vitro Models
The oily extracts 7 (a supercritical fluid extract) and 10 (a
commercial oil product by Marnys S.A., Spain), which are
characterized by the highest level of TQ, showed the most
remarkable effect on suppressing inflammatory mediators IL-
2, IL-6, and PGE2 released from human T-lymphocytes. In
addition, these two extracts showed a marked suppression of
IL-6 and PGE2 release in human monocytes. The extracts 1, 2,
and 8 also revealed a suppression of inflammatory mediators
in T-lymphocyte and monocytes but in a limited number of
mediators as compared to extracts 7 and 10, which showed a
much broader range of activities. On the other hand, the extracts
1, 2, 7, 8, 10 had a remarkable effect enhancing the release of
PGE2 from A549 human lung epithelial cells (Table 2). Therefore,
the oily extracts 7 and 10 showed the most potent and favorable
effects in the context of asthma, due to their anti-inflammatory
actions by suppressing the release of inflammatory mediators in
human immune cells (T-lymphocyte and monocyte cells) as well
as their possible bronchodilatory effect by enhancement of PGE2
release in A549 human lung epithelial cells.
DISCUSSION
The effects of NS preparations on the inhibition of inflammatory
mediators (IL-6, IL-2, PGE2) were investigated in human
primary T-lymphocyte cells, human primary monocytes, and
A549 lung epithelial cells. We show here that TQ-rich extracts
(especially extract no. 7 and 10) appeared to be the most potent
extracts in the context of anti-inflammatory/immunomodulatory
activity. The variability of the in vitro activity of NS preparations
correlates with differences in the chemical composition,
especially the TQ content, of the NS preparations. Furthermore,
our results showed that NS oil inhibited the release of some
cytokines with inflammatory properties, which are found to be
upregulated in patients with asthma. Therefore, NS may have
a corticosteroid-like effect in abolishing the upregulation of
some inflammatory mediators to induce remission of asthmatic
symptoms. Interestingly, NS also enhanced the release of PGE2,
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FIGURE 4 | Effects of NS preparations on interleukin-6 production in LPS-induced monocytes (n = 3). Significant effects are indicated by asterisks (∗∗P < 0.01,
∗∗∗P < 0.001).
FIGURE 5 | Effects of NS preparations on prostaglandin E2 release by LPS-induced monocytes (n = 3). Significant effects are indicated by asterisks (∗P < 0.05,
∗∗∗P < 0.001).
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FIGURE 6 | Effect of NS preparations on interleukin-6 production by interleukin-1β-induced A549 cells (n = 3). There was no significant effects.
FIGURE 7 | Effect of NS preparations on prostaglandin E2 production by interleukin-1β-induced A549 cells (n = 3). Significant effects are indicated by asterisks
(∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001).
which are thought to have a bronchodilatory effect in bronchial
epithelium. This study enabled us to identify the most active NS
preparations in various in vitro models of Asthma.
In human T-lymphocytes, the suppressive effect of NS on IL-
2, IL-6, and PGE2 release is not reported in the literature so
far. However, there was a suppression of serum IL-2 in mice
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TABLE 2 | Summary of the most active NS preparations by more than 50%
suppression or 150% enhancement of inflammatory mediators in cellular in vitro
models of inflammation (n = 3).
Sample T-Lymphocyte Cells Monocytes A549
IL-6 IL-2 PGE2 IL-6 PGE2 PGE2
Extract 1 ↓≥50% ↓≥50% ↓≥50% ↓≥50% ↑≥150%
Extract 2 ↓≥50% ↑≥150%
Extract 7 ↓≥50% ↓≥50% ↓≥50% ↓≥50% ↓≥50% ↑≥150%
Extract 8 ↓≥50% ↓≥50% ↓≥50% ↑≥150%
Extract 10 ↓≥50% ↓≥50% ↓≥50% ↓≥50% ↓≥50% ↑≥150%
treated with NS fixed oil (Abbas et al., 2005). This suppressive
effect on IL-2 release from T lymphocyte cells may be beneficial
in the context of asthma as it is considered a pro-inflammatory
mediator and found in a high level in BALF of patients with
asthma. The suppressive effects of NS on IL-6 release from SEB-
treated T lymphocytes may also be beneficial in the context of
asthma as IL-6 is considered as a pro-inflammatory mediator
and found at high levels in the serum of patients with asthma.
Also, the administration of NS volatile oil significantly lowered
the plasma level of PGE2 in rats (Salim, 2010). In in vitro
investigations, TQ caused a general anti-inflammatory activity
via inhibition of COX-1 and COX-2, which subsequently blocked
PGE2 production (Marsik et al., 2005). Carvacrol, a volatile oil
constituent of NS, inhibited the release of PGE2 catalyzed by
COX-2 (Landa et al., 2009a). This suppressive effect of PGE2
release from T-lymphocytes may be considered a favorable effect
due to the general pro-inflammatory properties of PGE2 and
the enhancement effect of PGE2 on Th2 and IgE responses.
Interestingly, there was a positive relationship between the TQ
level of the oily NS preparations and the inhibition of the
inflammatory mediators IL-2, IL-6, and PGE2.
In human monocytes, the anti-inflammatory effects observed
by the treatment with NS are not reported in the literature so far.
Some studies showed that TQ alone suppressed the expression of
IL-6 from Mycobacterium tuberculosis infected human monocyte
THP-1 cells (Mahmud et al., 2017). Furthermore, TQ inhibited
the production of IL-6 in LPS-activated murine macrophage-like
RAW264.7 cells (Hossen et al., 2017). These data are in line with
the data we obtained by TQ in LPS-induced human monocytes.
The suppressive effect of IL-6 release stimulated by LPS from
monocytes might be beneficial in the context of asthma as it
is considered a pro-inflammatory mediator and found in high
serum levels of patients with asthma. The inhibitory effect of NS
on LPS-induced PGE2 release in monocytes may be considered as
a favorable effect due to the general systemic pro-inflammatory
properties of PGE2 and the enhancement effect of PGE2 on Th2
and IgE responses.
We also present novel data on the effects of NS in A549
human lung epithelial cells, as we demonstrated an enhanced
release of IL-1-induced PGE2, but with no significant effect on
IL-6 synthesis. This is not in line with other studies in lung
tissues and cells. A previous study demonstrated that NS fixed oil
significantly suppressed mRNA IL-6 in whole lung tissue of rats
(Shahzad et al., 2009). Moreover, TQ suppressed the expression
of IL-6 from M. tuberculosis infected A549 cells (Mahmud
et al., 2017). Inhibitory effects of TQ were also shown for IL-6
expression in human proximal tubular epithelial cells stimulated
with advanced glycation end products (Sayed and Morcos, 2007).
Suppression of IL-6 may possess beneficial anti-inflammatory
effects in bronchial epithelial cells of asthmatic patients (Mattoli
et al., 1992). Unlike beta-agonists (a conventional treatment in
asthma), which can enhance IL-6 expression in the lung, NS
had no, or only mild inhibitory effects on IL-1-induced IL-6
release (Edwards et al., 2007). The stimulatory effect of NS on
PGE2 release from A549 human lung epithelial cells has not been
reported so far. However, increased PGE2 release was shown in
perfused guinea-pig lung preparation using NS oil (Saleh et al.,
2012). Interestingly, the increased PGE2 release by TQ-rich NS
preparations may have a favorable effect in the context of asthma
as several studies showed that PGE2 may possess beneficial local
protective and bronchodilatory effects in the airways of the lung
(Chung, 2005; Sastre and Del Pozo, 2012; Torres et al., 2015).
This in vitro study served as a basis for developing the clinical
study of NS oil in patients with asthma conducted by our group
(Koshak et al., 2017b). Consequently, the mediators investigated
here were general inflammatory targets associated with asthma.
In addition, it would be of interest to investigate other classical
targets in asthma disease and to compare the effects of NS
preparations on the release of Th2 cytokines IL-4, IL-5, and IL-13
in in vitro models.
CONCLUSION
The results of this work showed variability in the anti-
inflammatory/immunomodulatory effects of different NS
preparations. Direct in vitro evidence points to the release
of some asthma-related cytokines and a prostanoid with
inflammatory properties (IL-2, IL-6, PGE2) from human
immune cells (including T-lymphocytes and monocytes). These
were potently modulated by NS preparations rich in fatty oils.
There was a positive relationship between the levels of TQ and
the inhibition of inflammatory mediators in T-lymphocytes
and monocytes. Interestingly, the oily preparations showed an
increase in PGE2 production in lung epithelial cells, which may
possess a favorable effect in the context of asthma. Ultimately,
the oily TQ-rich NS preparations appeared to be the most potent
preparations and are recommended for further investigations in
clinical trials.
More broadly, this method of pharmacological screening
combined with a chemical analysis of single or more active
compounds should be implemented for other herbal products
to identify most active chemically characterized preparations.
Such chemical analysis of active compounds is essential prior
to using plant extracts in clinical studies. This is of a particular
importance for many herbal medicines currently under clinical
and preclinical investigation in the fast-developing economies of
the global South. Also, further investigations are suggested on
the effect of NS on other inflammatory mediators as well as the
mechanism by which these mediators are inhibited.
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